Pharma Pulse 6/4/24: Google Rolls Back AI Search Feature, More GLP-1s are on Their Way & more

AI-Enabled Clinical Trials: A Multiomic Roadmap to Success

How artificial intelligence can aid in selecting patients, leveraging safety insights, and optimizing combination therapies.

It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way.

These days, glucagon-like peptide 1 (GLP-1) receptor agonists need no introduction; they are the hot topic in professional meetings and conferences, in Hollywood and on TikTok. Part of a broader class of drugs called incretin mimetics, GLP-1s entered the market as treatments for type 2 diabetes and exploded as the newest drugs for chronic weight management for people living with obesity and for those who are overweight with conditions related to being overweight.

Improve Site Experience with Data-Driven Protocol Design

Sites can encounter a wide range of challenges when operationalizing study protocols, including the need to manage frequent and lengthy patients visits, coordinate complicated procedure schedules and utilize multiple disparate technology systems. Applied analytics enable data-driven protocol design that can help sponsors mitigate these trial challenges.

Data collected from sites can help uncover specific protocol elements that drive sites’ perception of burden. These findings can be used to optimize protocol design to decrease burden and improve site experience, potentially leading to positive outcomes such as facilitating the collection of cleaner data and improving protocol compliance.

Google Rolls Back A.I. Search Feature After Flubs and Flaws

Google appears to have turned off its new A.I. Overviews for a number of searches as it works to minimize errors.

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Inc. has unveiled the Thermo Scientific™ Stellar™ mass spectrometer, a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

@NASCSA on X/Twitter:

FDA Approves Tris Pharma’s Onyda XR, a Once-Daily, Extended-Release Oral Suspension for the Treatment of ADHD via @PharmExec

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs